Big data in MS—What can we learn from large international observational studies such as MSBase?

Abstract

Get full access to this article

View all access options for this article.

References

Cree

BAC

Mares

Hartung

HP.

Current therapeutic landscape in multiple sclerosis: An evolving treatment paradigm. Curr Opin Neurol 2019; 32(3): 365–377.

Fambiatos

Jokubaitis

Horakova

, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler 2020; 26: 79–90.

Lorscheider

Buzzard

Jokubaitis

, et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139: 2395–2405.

Brown

JWL

Coles

Horakova

, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187.

Kalincik

Brown

JWL

Robertson

, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: A cohort study. Lancet Neurol 2017; 16(4): 271–281.